Real-world data from the P-VERIFY study didn’t find any notable OS improvements between multiple CDK4/6 inhibitor combos in metastatic breast cancer.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

During an FDA Special Session, field experts talked about the NATALEE trial and further information gathering on adjuvant ribociclib in breast cancer.

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.